Dr. Reddy's Laboratories has officially announced the launch of Obeda®, India's first DCGI-approved generic semaglutide injection for Type 2 diabetes management. This milestone positions the company as the first Indian pharmaceutical firm to receive Drugs Controller General of India approval for generic semaglutide, marking its Day-1 entry into the GLP-1 receptor agonists therapy space.

Clinical Efficacy and Safety Profile

The launch follows successful completion of a comprehensive Phase III clinical study that enrolled 312 participants. The head-to-head comparison demonstrated Obeda®'s non-inferior efficacy and safety profile comparable to the innovator drug.

Product Specifications and Pricing

Obeda® semaglutide injection comes in a user-friendly format designed for patient convenience and adherence. The product addresses India's significant diabetes burden, with over 101 million adults living with the condition according to the ICMR-INDIAB study.

In-house Development Capabilities

Dr. Reddy's developed both API and formulation entirely in-house, demonstrating its strength in complex product development and peptide science. This approach reflects the company's decade-long expertise in peptide technology and commitment to bringing GLP-1 therapies to market.

Erez Israeli, Chief Executive Officer of Dr. Reddy's, emphasized the significance: "Today's launch marks a significant step in our commitment to expand our portfolio in critical therapeutic areas with differentiated solutions to patients in India and across global markets. Our foray into GLP-1 therapies reflects our capabilities in complex product development and peptide science."

Patient Support and Market Strategy

The company has developed SemaKare™, a comprehensive patient support system enhanced by a digital app. This platform provides onboarding guidance and field device-counsellor assistance, injection training and tele-support services, therapy-adherence monitoring, and treatment outcome improvement initiatives.

Dr. Reddy's plans to establish metabolic centres of excellence across India, serving as integrated hubs for advancing diabetes and metabolic disorders treatment. These centres will focus on healthcare professional education, evidence-based management, and real-world evidence generation.

Global Expansion Plans

As part of its phase-1 launch strategy, Dr. Reddy's aims to introduce generic semaglutide in several countries, subject to regulatory approval. The company's "One Product, One Quality" approach ensures consistent high-quality standards across all markets.

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), stated: "As the first generic semaglutide approved in the country, today's announcement reflects our science-led approach and our long-standing efforts in expanding access to advanced therapies in India."

Dr. Reddy's Laboratories has disclosed receiving three separate tax demand orders from the GST Authority for the financial years 2019-20 to 2021-22. The pharmaceutical company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on March 17, 2026.

GST Authority Orders Details

The orders were issued by the Commercial Taxes Department – Office of the Joint Commissioner (ST), Chennai Intelligence -II. The company received these orders dated March 16, 2026, on the same day. The authority has passed the orders under section 74 of the TNGST Act, 2017, seeking demand including interest and penalty.

The GST Authority has primarily based these orders on the ground that certain supplies are taxable in nature, according to the company's disclosure.

Financial Impact and Penalty Breakdown

The orders levy penalties across three financial years with varying amounts:

The total penalty amount across all three financial years sums to ₹2,20,03,734, with the FY 2019-20 penalty constituting the overwhelming majority of the demand.

Company's Response and Assessment

Dr. Reddy's Laboratories has stated that based on its evaluation, there is no material impact on the financials, operations, or other activities of the company. The pharmaceutical major indicated that it will evaluate filing necessary appeals with the appellate authority regarding these orders.

The disclosure was signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR, ensuring compliance with regulatory requirements for material disclosures to stock exchanges.